Syntekabio Appoints Joonhyuk Choi as Head of US Operations

Syntekabio (KOSDAQ: 226330), a leading artificial intelligence (AI)-driven drug development company, has announced the appointment of Joonhyuk Choi, former CEO of Target Health, as Head of US Operations. This appointment is set to bolster Syntekabio's strategic initiatives and expand its footprint in the US market.

Joonhyuk Choi brings over 25 years of experience in the pharmaceutical industry, with a strong academic background in electrical and computer engineering from Rutgers University in New Jersey. His career is marked by significant achievements in developing clinical trial software, navigating the US FDA's drug and medical device approval processes, managing clinical trials, and driving business development success.

Prior to joining Syntekabio, Choi served as CEO of Target Health, a US-based contract research organization (CRO). In this role, he played a pivotal part in clinical operations and business development, leading sales and marketing teams and overseeing the development and maintenance of validated software solutions for clinical trials and data management for over two decades.

Syntekabio anticipates that Choi's deep understanding of the drug development process, from AI-driven drug discovery and clinical trials to drug approvals, coupled with his extensive knowledge of the US market, will significantly enhance the company's strategic partnerships and revenue-generating initiatives. Choi's role is expected to be crucial in driving Syntekabio's global expansion and enhancing its competitiveness in the AI drug discovery sector.

Joonhyuk Choi expressed his enthusiasm for joining Syntekabio, stating, "I am honored to join Syntekabio at such a pivotal moment in the company’s journey. I am committed to leveraging strategies tailored to the unique dynamics of the US pharma and biotech market to enhance the global reach and impact of Syntekabio’s AI drug discovery platform."

Jongsun Jung, PhD, CEO of Syntekabio, remarked, "With Joonhyuk’s appointment, Syntekabio is now strategically positioned to collaborate with potential partners across the entire drug development spectrum, from AI-driven candidate screening to clinical trials. His extensive expertise and experience in the US market will be crucial in driving our global expansion and enhancing our competitiveness, positioning us for achieving sustained business success."

Syntekabio, established in 2009, is a drug discovery company that combines biology with AI/ML to facilitate the discovery of first-in-class and best-in-class compounds rapidly. The company utilizes its own supercomputer cloud and a global contract research organization network to complement and validate its computational results. Syntekabio offers clients a comprehensive range of technologies and tailored services to rapidly generate and optimize drug candidates from target to IND-enabling. The company's disease-agnostic physics-based platform generates a continuous stream of hits, leads, and drug candidates that are readily available for purchase. Additionally, Syntekabio undertakes client-specific projects to identify highly promising development candidates for specific targets and indications.